vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and BRC Group Holdings, Inc. (RILY). Click either name above to swap in a different company.
BRC Group Holdings, Inc. is the larger business by last-quarter revenue ($188.3M vs $168.4M, roughly 1.1× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs -21.9%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs -15.4%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
ESPR vs RILY — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $188.3M |
| Net Profit | — | $90.3M |
| Gross Margin | — | 79.5% |
| Operating Margin | 50.6% | 32.3% |
| Net Margin | — | 47.9% |
| Revenue YoY | 143.7% | -21.9% |
| Net Profit YoY | — | 1710.8% |
| EPS (diluted) | $0.32 | $2.78 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $168.4M | $188.3M | ||
| Q3 25 | $87.3M | $215.3M | ||
| Q2 25 | $82.4M | $188.2M | ||
| Q1 25 | $65.0M | $197.2M | ||
| Q4 24 | $69.1M | $241.0M | ||
| Q3 24 | $51.6M | $225.5M | ||
| Q2 24 | $73.8M | $256.0M | ||
| Q1 24 | $137.7M | $263.4M |
| Q4 25 | — | $90.3M | ||
| Q3 25 | $-31.3M | $91.1M | ||
| Q2 25 | $-12.7M | $139.5M | ||
| Q1 25 | $-40.5M | $-10.0M | ||
| Q4 24 | — | $-5.6M | ||
| Q3 24 | $-29.5M | $-284.4M | ||
| Q2 24 | $-61.9M | $-433.6M | ||
| Q1 24 | $61.0M | $-49.2M |
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 83.7% | ||
| Q2 25 | — | 81.3% | ||
| Q1 25 | — | 81.4% | ||
| Q4 24 | — | 79.8% | ||
| Q3 24 | — | 82.1% | ||
| Q2 24 | — | 84.5% | ||
| Q1 24 | — | 85.3% |
| Q4 25 | 50.6% | 32.3% | ||
| Q3 25 | -11.4% | 30.4% | ||
| Q2 25 | 8.6% | 5.7% | ||
| Q1 25 | -34.0% | -31.2% | ||
| Q4 24 | -6.4% | -69.2% | ||
| Q3 24 | -31.0% | -36.4% | ||
| Q2 24 | 3.5% | -90.8% | ||
| Q1 24 | 52.5% | -6.1% |
| Q4 25 | — | 47.9% | ||
| Q3 25 | -35.9% | 42.3% | ||
| Q2 25 | -15.4% | 74.1% | ||
| Q1 25 | -62.2% | -5.1% | ||
| Q4 24 | — | -2.3% | ||
| Q3 24 | -57.2% | -126.1% | ||
| Q2 24 | -83.9% | -169.4% | ||
| Q1 24 | 44.3% | -18.7% |
| Q4 25 | $0.32 | $2.78 | ||
| Q3 25 | $-0.16 | $2.91 | ||
| Q2 25 | $-0.06 | $4.50 | ||
| Q1 25 | $-0.21 | $-0.39 | ||
| Q4 24 | $-0.14 | $-0.01 | ||
| Q3 24 | $-0.15 | $-9.39 | ||
| Q2 24 | $-0.33 | $-14.35 | ||
| Q1 24 | $0.34 | $-1.71 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $226.6M |
| Total DebtLower is stronger | — | $1.4B |
| Stockholders' EquityBook value | $-302.0M | $-171.5M |
| Total Assets | $465.9M | $1.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.9M | $226.6M | ||
| Q3 25 | $92.4M | $184.2M | ||
| Q2 25 | $86.1M | $267.4M | ||
| Q1 25 | $114.6M | $138.3M | ||
| Q4 24 | $144.8M | $146.9M | ||
| Q3 24 | $144.7M | $159.2M | ||
| Q2 24 | $189.3M | $236.9M | ||
| Q1 24 | $226.6M | $190.7M |
| Q4 25 | — | $1.4B | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | — | $1.3B | ||
| Q1 25 | — | $1.4B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-302.0M | $-171.5M | ||
| Q3 25 | $-451.4M | $-260.5M | ||
| Q2 25 | $-433.5M | $-351.7M | ||
| Q1 25 | $-426.2M | $-496.8M | ||
| Q4 24 | $-388.7M | $-488.2M | ||
| Q3 24 | $-370.2M | $-497.6M | ||
| Q2 24 | $-344.2M | $-218.3M | ||
| Q1 24 | $-294.3M | $228.4M |
| Q4 25 | $465.9M | $1.7B | ||
| Q3 25 | $364.0M | $1.7B | ||
| Q2 25 | $347.1M | $1.5B | ||
| Q1 25 | $324.0M | $1.5B | ||
| Q4 24 | $343.8M | $1.8B | ||
| Q3 24 | $314.1M | $2.2B | ||
| Q2 24 | $352.3M | $3.2B | ||
| Q1 24 | $373.1M | $5.0B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | $26.2M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | 0.29× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.2M | $26.2M | ||
| Q3 25 | $-4.3M | $-60.6M | ||
| Q2 25 | $-31.4M | $-25.6M | ||
| Q1 25 | $-22.6M | $184.0K | ||
| Q4 24 | $-35.0M | $-2.7M | ||
| Q3 24 | $-35.3M | $19.5M | ||
| Q2 24 | $-7.2M | $111.5M | ||
| Q1 24 | $53.8M | $135.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-35.5M | — | ||
| Q2 24 | $-7.3M | — | ||
| Q1 24 | $53.8M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -68.7% | — | ||
| Q2 24 | -9.9% | — | ||
| Q1 24 | 39.0% | — |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.3% | — | ||
| Q2 24 | 0.1% | — | ||
| Q1 24 | 0.1% | — |
| Q4 25 | — | 0.29× | ||
| Q3 25 | — | -0.66× | ||
| Q2 25 | — | -0.18× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.88× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
RILY
| Transferred At Point In Time | $101.4M | 54% |
| Wealth Management Segment | $30.7M | 16% |
| Corporate Finance Consulting And Investment Banking Fees | $27.1M | 14% |
| Services And Fees | $24.8M | 13% |
| Commissions Fees And Reimbursed Expenses | $4.8M | 3% |
